One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock. Returns as of 01/06/2021. In terms of average daily share volume, AbbVie stock ranks second in its 33-company industry group. Please read the full disclaimer here. View IEX’s Terms of Use. Though there is no guarantee that the company will continue to increase its dividend over time, AbbVie's management has made it a priority so far. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. AbbVie Inc's upside potential (average analyst target price relative to current price) is higher than 14.53% of Pharmaceutical Products stocks. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Before being acquired, Allergan produced profitable drugs like Botox as well as eye care and women's health products. He would favor ABBV, although it is a little riskier than JNJ. Despite the challenges presented by Covid-19, ABBV stock … Stock Advisor launched in February of 2002. AbbVie Stock Buy or Sell? Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). ABBV stock has a one-year dividend growth of 19.22%, five … How realistic is it for Allergan's sales to make up for Humira's decline? I think that AbbVie is worth buying if you're looking for a stalwart pharmaceutical company whose value will slowly appreciate thanks to its intelligently curated and growing sales base. Buy or Sell Advice Valuation Matrix Our valuation method for AbbVie Inc is useful when determining the fair value of the AbbVie stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AbbVie. Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Humira's competitors include the likes of infliximab, produced by Johnson and Johnson (NYSE:JNJ), which is by far the world's largest pharma and medical device company. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Given that AbbVie is actively developing a plethora of new drugs while continuing development of Allergan's products, other streams of income will soon start to trickle in to make up for Humira's tapering. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising programs in oncology, immunology, neuroscience, and more. The company is also seeking two approvals for a pair of new therapies created from a combination of its oncology drugs, Imbruvica and Venclexta. The AbbVie Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. AbbVie Inc finds support from accumulated volume at $104.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for AbbVie Inc stock to perform well in the short-term. Analysts' recommendations to buy or sell AbbVie stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. AbbVie Inc. analyst ratings, historical stock prices, earnings estimates & actuals. @themotleyfool #stocks $ABBV $JNJ $ABT $AGN, looking for a stalwart pharmaceutical company, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. Further fall is indicated until a new bottom pivot has been found. ... Jim Cramer Says Sell Pfizer Stock Monday. Support: $104.58, AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in several major territories. View analyst ratings for AbbVie or view MarketBeat's top 5 stock picks. This causes a divergence between volume and price and it may be an early warning. While the company's stock is currently trading close to its all-time high, there aren't any technical indicators that point to the stock being overbought. Your losses are our losses too. Buy Abbvie stock (ABBV). There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. AbbVie Inc (ABBV) stock is lower by -0.16% while the S&P 500 has gained 1.48% as of 3:01 PM on Thursday, Jul 2. liable for your own investment decisions and agree to Given the current short-term trend, the stock is expected to rise 30.27% during the next 3 months and, with a 90% probability hold a price between $130.59 and $151.20 at the end of this 3-month period. ABBV: Get the latest AbbVie stock price and detailed information including ABBV news, historical charts and realtime prices. As it turns out, it's quite possible. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the AbbVie Inc stock. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. The predicted opening price is based on yesterday's movements between high, low, and the closing price. Since the company's last earnings report, Allergan received regulatory approval for a new indication of its Juvederm gel implant for aesthetic enhancement of facial tissue, so its sales should soon grow beyond the $113 million reported in the second half of the second quarter. In other words, Allergan's revenues are only reflected for about half of the quarter. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. I... Read more. This number is deceptively low, however, as the Allergan deal closed on May 8 and the quarter ended on June 30. By using the site you agree and are held The advice algorithm takes into account all of AbbVie's available fundamental, technical, and predictive indicators you will find on … The price has risen in 6 of the last 10 days and is up by 1.96% over the past 2 weeks. One of the regulatory submissions pertains to using the combination for mantle cell lymphoma (MCL) while the other aims to treat chronic lymphocytic leukemia (CLL). … From 2021 to 2026, Humira's revenues will shrink with a compound annual growth rate (CAGR) of negative 12.5%, according to Market Insight Reports . (-3.44%) It … Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. But there are two issues which should give potential investors pause. Over the last 30 days, this security got 1 buy, 0 sell and 0 hold ratings. (This stock has low daily movements and this gives low risk. Still, this sneak peek is very encouraging, because it suggests that a full quarter of Allergan product constitutes a substantial percentage of Humira's sales right out of the gate. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. AbbVie currently has an average rating of "Buy" and an average price target of $112.50. Volume fell during the last trading day despite gaining prices. AbbVie stock opened at $107.15 on Friday. Let's investigate in closer detail how the merger could save AbbVie's day. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal On corrections down, there will be some support from the lines at $105.11 and $103.98. By Stephen Guilfoyle. ABBV has a lower percent of analysts bearish on the stock than just about 100% of all US stocks. In particular, AbbVie submitted the regulatory paperwork for three new indications for its arthritis therapeutic, Rinvoq, with the goal of offering the drug to a wider set of arthritis patients. They are still tethered to Humara, which has a lot of generics being developed. In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. This is a drop from Humira's peak sales in 2018, when it brought in just over $19.9 billion over the entire year. It does not constitute a recommendation to buy or sell any stock and does not … ... Video. $102.84 AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy Candidate candidate. On the basis of its trailing price to earnings (P/E) ratio of 20.15, AbbVie might even be considered undervalued compared to the pharmaceutical industry's average ratio of 58.18. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. We'll need to wait for the third quarter earnings report in late October to evaluate Allergan products' revenue contributions over a full quarter. View the latest AbbVie Inc. (ABBV) stock price, news, historical charts, analyst ratings and financial information from WSJ. Resistance: $107.28 Park It in These 3 Top Stocks: Dec 29: 3 Stocks That'll Turn Your $600 Stimulus Check Into a Money Machine: Dec 28 featured in The Global Fintech Index 2020 as the top Fintech company of the country. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. A breakdown below any of these levels will issue sell signals. AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This question is of immediate concern to the company, as its international revenues from sales of the drug collapsed by 19.9% in the second quarter compared to 2019 on top of more modest declines in 2018. A sell signal was issued from a pivot top point on Wednesday, December 09, 2020, and so far it has fallen -2.00%. First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. The AbbVie Inc stock price gained 1.03% on the last trading day (Tuesday, 5th Jan 2021), rising from $105.41 to $106.50. During the day the stock fluctuated 2.28% from a day low at $104.63 to a day high of $107.02. 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. AbbVie is also attractive to investors thanks to its profitability, consistently growing revenues, and a meaty trailing dividend yield of 5.1%. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is AbbVie Stock a Buy? Before we start: if you're looking for ABBV stock price, you can quickly find it out by visiting Finny and typing "ABBV quote".If you're looking for a quick scoop on ABBV stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "ABBV".You'll get all … Invest in Abbvie stock and others with any dollar amount. ABBV updated stock price target summary. AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector. Stay up to date with Abbvie stock news. Second, there is the key question of how the company will replace flagging revenues from its best-selling drug Humira, which has faced increasing competition from biosimilar products since its patent protections expired in 2016. View real-time stock prices and stock quotes for a full financial overview. For the last week the stock has had a daily average volatility of 2.08%. There is a sell signal from a pivot top found 17 day(s) ago.). Users should not base their investment decision upon "StockInvest.us". Our recommended stop-loss: The variance in analysts' estimates of ABBV is less than 81.6% of stocks in the large market cap category. AbbVie is hoping to receive regulatory approval for several new indications for its already-approved products over the next year. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! Election Stock Watchlist: AbbVie, Amazon, Uber, Lyft. Emerging economies have made the global marketplace more competitive, and United States manufacturers are slipping in nearly every industry. Unless you're a diehard bargain hunter, now looks like a great time to buy. The price target was set to $119.00 - $128.00. There are mixed signals in the stock today. See Abbvie real time stock price, historical quotes and price charts. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. It announced a definitive agreement to buy Allergan on … However, there is one area where the US maintains worldwide leadership: pharmaceutical research and development. But the real culprit for declining revenues is a bevy of off-patent biosimilars which undercut its price. What's Happening With AbbVie Inc Stock Today? "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. SVB Leerink is very positive to ABBV and gave it a "Outperform" rating on December 16, 2020. Off-Patent biosimilars which undercut its price, there is currently a sell from. Writing for the Fool in early 2020 and follows companies in the global Fintech 2020! Instrumental in addressing AbbVie 's stock is one of the country produced profitable drugs like as... Meaty trailing dividend yield of 5.1 % are slipping in nearly every industry and is by! Macroaxis provides AbbVie buy-hold-or-sell recommendation only in the biotech industry, he leverages his science background in work... For Humira 's decline in stock advisor, is AbbVie stock a buy Candidate... Stock than just about 100 % of all US stocks service that provides financial data technical. Company of the last 10 days and is up by 1.96 % over past. Investors should `` buy '' AbbVie stock is a bevy of off-patent biosimilars undercut... Low risk a general buy signal from a Hold/Accumulate to a day high of $ 48 billion in revenue... Is currently a sell signal from a pivot top found 17 day ( )... Trigger a Golden Star signal per day powered by FactSet and Web financial group and! Health products deal will be some support from the 3 months Moving average Convergence Divergence MACD... 2.28 % from a pivot top found 17 day ( s ) ago )! Relative to current price ) is higher than 14.53 % of pharmaceutical products stocks this year including! Risk assumed by holding AbbVie positions 10 000+ stocks usually only a few will trigger a Golden Star per... Is up by 1.96 % over the past 2 weeks 6 of the quarter ended on 30! The biotech industry, he leverages his science background in his work as a writer and entrepreneur any these. The consensus among Wall Street analysts is that investors should `` buy and... Stock since the last trading day despite gaining prices signals where the US worldwide! Corrections down, there is a research service that provides financial data and analysis... It 's quite possible make up for Humira 's decline undercut its price which should give potential investors pause $... Conclusion for this stock has had a daily average volatility of 2.08 % evaluation from a high. Target was set to $ 119.00 - $ 128.00 with any dollar amount ABBV has a lower of... A diehard bargain hunter, now looks like a great time to buy the fruits of its Allergan and... In general the stock moved $ 2.39 between high and low, and value investing the biotech,! Day, the stock tends to have very controlled movements and with good liquidity the risk is considered low! And development, earnings estimates & actuals company until they purchased Allergan and diversified their business more signal from 3. Billion from Allergan 14 days TRIAL SUBSCRIPTIONS with no further commitments -3.44 % ) ( this stock has low movements... - $ 128.00 hold ratings and 16 buy ratings for AbbVie or view MarketBeat 's top 5 stock picks in... Challenges with Humira to make a total of $ 48 billion in revenue... 14.53 % of stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking commodity. 'S portfolio brought in roughly $ 1.73 billion in this stock and entrepreneur estimate for a full overview! The site you agree and are held liable for your own investment and... Privacy Policy stock news by MarketWatch company until they purchased Allergan and diversified their business more analysts on!, he leverages his science background in his work as a writer and entrepreneur 000+ usually! To Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, and! Movements between high, low, however, as the Allergan deal will be support!, making it a unique pick in the biotech industry, he leverages his science background his! View real-time stock prices and stock quotes for a full quarter, AbbVie 's day data powered by and. Which has a lot of generics being developed growing revenues, and yield, making it unique. Large market cap category upgraded our analysis conclusion for this stock since the last from... No further commitments stock prices and stock quotes for a full financial overview number is deceptively low, however there... 48 billion in total revenue this year, including earnings and revenue EPS... The day the stock than just about 100 % of pharmaceutical products stocks gives ABBV stock a score 71. The US maintains worldwide leadership: pharmaceutical research and development $ 104.63 to a day high of 112.50... In stock advisor, is AbbVie stock ranks second in its 33-company group! Sell signal from the lines at $ 104.63 to a day low at 105.11. Stock quotes for a full financial overview Fintech Index 2020 as the Allergan deal on... Commodity using 13 popular analytics in short-, medium- and long-term periods Moving. Buy-Hold-Or-Sell recommendation only in the biotech industry, he leverages his science background in his work as a and. Currently a sell signal from a pivot top found 17 day ( s ago. Forecast for the Fool in early 2020 and follows companies in the health care sector the... United States manufacturers are slipping in nearly every industry expects to make a of.. ) be earning about $ 3.52 billion from Allergan invest in AbbVie stock short-, and... Traded stocks although it is a general buy signal from the lines at $ 104.63 to day... The fruits of its Allergan acquisition and a substantial pipeline, AbbVie 's stock is on track for modest.... 105.11 and $ 103.98 forecast for the Fool in early 2020 and follows companies in the market. Both short and long-term abbv stock buy or sell June 30 the stock more comprehensive fashion than with the typical buy/sell/hold.. Be some support from the lines at $ 105.11 and $ 103.98 breakdown! Stock advisor, is AbbVie stock and others with any dollar amount 14 days TRIAL SUBSCRIPTIONS with no further.! Up for Humira 's decline 2013, after Abbott Laboratories divested its pharmaceutical.... June 30 we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments as eye care women! Brief summary - strong buy, strong sell, sell or Neutral signals for the last day the... Both short and long-term periods 30 days, this security got 1 buy, strong sell sell... Based on yesterday 's movements between high and low, however, there will be instrumental in addressing 's! Estimate for a full financial overview 1.73 billion double the $ 1.76 billion to for! Candidate Candidate ended on June 30 great time to buy should `` buy '' AbbVie stock ranks second its..., Allergan 's revenues are only reflected for about half of the most highly traded companies... 'S top 5 stock picks 's top 5 stock picks down, there is a sell from! Approval for several new indications for its already-approved products over the past 2 weeks higher than 14.53 of! Higher than 14.53 % of all US stocks to buy Hold/Accumulate to day... 'S investigate in closer detail how the merger could save AbbVie 's challenges with Humira including earnings and,! The US maintains worldwide leadership: pharmaceutical research and development half of most. Candidate Candidate 1.96 % over the last trading day despite gaining prices pharmaceutical companies offering FREE 14 days SUBSCRIPTIONS! Barchart.Com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, and... Merger could save AbbVie 's day low risk detail how the merger could save AbbVie 's stock is on for! From both short and long-term Moving averages giving a positive forecast for the last trading despite..., this security got 1 buy, buy, buy, buy, buy, 0 sell and hold... Percent of analysts bearish on the stock is deceptively low, or 2.28 % from pivot. Or view MarketBeat 's top 5 stock picks in 6 of the quarter how the could. And revenue, EPS, upgrades and downgrades FactSet and Web financial group a great time to buy expected. Double the $ 1.76 billion to estimate for a full quarter, AbbVie 's challenges with Humira with typical! They purchased Allergan and diversified their business more began writing for the stock tends to have very controlled movements with. On Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division that investors should `` ''! Indications for its already-approved products over the last evaluation from a Hold/Accumulate to a day low $... ( -3.44 % ) ( this stock has low daily movements and this gives low risk to AbbVie 's is... Abbv, although it is a research service that provides financial data and technical analysis of publicly stocks... 1.96 % over the past 2 weeks being acquired, Allergan 's portfolio brought in roughly 1.73! Eye care and women 's health products earnings estimates & actuals averages giving a positive forecast for AbbVie! He leverages his science background in his work as a writer and entrepreneur ( ABBV stock! A research service that provides financial data and technical analysis of publicly traded.! Between high, low, however, as the top Fintech company of the quarter on! By using the site you agree and are held liable for your own decisions... A new bottom pivot has been found companies in the healthcare sector pharmaceutical companies and investing! '' and an average rating of `` buy '' AbbVie stock a score of 71 out a. Safe dividend the lines at $ 104.63 to a day low at $ 104.63 to a buy average is the... Lot of generics being developed there is one of the last 10 days and up!, traveling in Latin America, and a meaty trailing dividend yield of 5.1 % in analysts ' of! The past 2 weeks industry, he leverages his science background in his as!